<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital toxoplasmosis: Treatment, outcome, and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital toxoplasmosis: Treatment, outcome, and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital toxoplasmosis: Treatment, outcome, and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicholas G Guerina, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lucila Marquez, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4829118"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Toxoplasma gondii</em> is a ubiquitous protozoan parasite that infects animals and humans. <em>Toxoplasma</em> infection typically is asymptomatic in immunocompetent hosts. However, serious disease can occur, most frequently in the setting of immunosuppression or congenital infection. The fetus, newborn, and young infant with congenital <em>Toxoplasma</em> infection are at risk of infection-associated complications, particularly retinal disease that can continue into adulthood.</p><p>The treatment, outcome, and prevention of congenital toxoplasmosis will be reviewed here. The clinical features and diagnosis of congenital toxoplasmosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis"</a>.)</p><p>Toxoplasmosis in other patient populations is discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy (see  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompetent hosts (see  <a class="medical medical_review" href="/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>HIV-infected patients (see  <a class="medical medical_review" href="/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a>)</p><p></p><p class="headingAnchor" id="H4829759"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H4829767"><span class="h2">Antiparasitic therapy</span></p><p class="headingAnchor" id="H4829774"><span class="h3">Whom to treat</span><span class="headingEndMark"> — </span>Decisions about treatment and follow-up testing should be made in consultation with an infectious disease specialist and reference laboratory. Antiparasitic therapy is generally appropriate for infants (&lt;12 months old) in whom a diagnosis of congenital toxoplasmosis is confirmed or highly likely, including [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatally diagnosed infants</strong> – Infants diagnosed with congenital toxoplasmosis prenatally are treated postnatally, regardless of whether the mother received treatment during pregnancy. (See  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Prenatal diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic infection</strong> – For infants with clinical findings compatible with congenital toxoplasmosis (eg, chorioretinitis, intracranial calcifications, hydrocephalus), treatment is indicated if any of the following criteria are met:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis is confirmed with serology or polymerase chain reaction (PCR) performed by a reference laboratory. (See  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The mother has recent documented <em>T. gondii</em> infection – In these infants, <em>T. gondii</em> infection should be confirmed (with maternal and infant serology and infant cerebrospinal fluid [CSF] PCR) and, in the absence of confirmative tests, alternative etiologies should be excluded (eg, congenital cytomegalovirus, Zika virus if maternal exposure risk is identified). (See  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/109681.html" rel="external">"Congenital Zika virus infection: Clinical features, evaluation, and management of the neonate"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial newborn serology results are equivocal – It is reasonable to start treatment in symptomatic infants with equivocal serology pending definitive testing, which may take months. If definitive testing does not confirm <em>T. gondii</em> infection, alternative diagnoses should be excluded. (See  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Repeat testing'</a> and  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic or preclinical infection</strong> – For infants with confirmed <em>T. gondii</em> infection (with serology or PCR performed by a reference laboratory) who lack supportive clinical findings, we suggest antiparasitic treatment. In addition, it is reasonable to treat asymptomatic infants who have equivocal newborn serology, pending definitive testing (which may take months) [<a href="#rid3">3</a>]. The rationale for treating this group is to reduce the risk of late sequelae. Observational data suggest that early and prolonged treatment of asymptomatic infants may reduce long-term sequelae [<a href="#rid4">4</a>]. Deferring treatment in these infants is a reasonable alternative; however, there is a risk of late sequelae in untreated congenital toxoplasmosis. (See <a class="local">'Efficacy'</a> below.)</p><p></p><p class="headingAnchor" id="H4829781"><span class="h3">Treatment regimen</span></p><p class="headingAnchor" id="H2831389827"><span class="h4">Preferred regimen</span><span class="headingEndMark"> — </span>The preferred antiparasitic regimen consists of <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> plus <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">sulfadiazine</a> (or sulfamerazine or sulfamethazine) and folinic acid (<a class="drug drug_pediatric" data-topicid="12544" href="/d/drug information/12544.html" rel="external">leucovorin</a>) [<a href="#rid2">2,5-7</a>]. Treatment protocols are not standardized, and there is considerable variation in practice in different parts of the world.</p><p>Data on comparative efficacy of different postnatal treatment protocols are lacking, and the choice depends on drug availability and the experience of the treating clinician or center [<a href="#rid6">6</a>]. Sulfamerazine and sulfamethazine are not available in the United States. The optimal doses and duration for these drugs are not established definitively and should be determined in consultation with specialists in pediatric infectious diseases.</p><p>We suggest:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">Pyrimethamine</a> 2 mg/kg (maximum 50 mg/dose) once daily for two days, then 1 mg/kg (maximum 25 mg/dose) once daily for six months, and then 1 mg/kg (maximum 25 mg/dose) three times per week (ie, Monday, Wednesday, and Friday) to complete one year of therapy, <strong>plus</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">Sulfadiazine</a> 50 mg/kg every 12 hours, <strong>plus</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Folinic acid (<a class="drug drug_pediatric" data-topicid="12544" href="/d/drug information/12544.html" rel="external">leucovorin</a>) 10 mg three times per week during and for one week after <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> therapy</p><p></p><p>The infant should be weighed weekly and the doses adjusted for weight gain [<a href="#rid1">1</a>]. <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">Pyrimethamine</a> should be temporarily withheld if the absolute neutrophil count (ANC) falls below 500 cells/microL. The dose of folinic acid may be increased as needed if the ANC falls below 1000 cells/microL. (See <a class="local">'Adverse effects'</a> below and <a class="local">'Therapeutic monitoring'</a> below.)</p><p>One year of treatment is recommended by many experts, though some centers extend treatment up to two years [<a href="#rid1">1-3,5-9</a>].</p><p>Glucocorticoids (<a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> 0.5 mg/kg twice daily) are added if CSF protein is &gt;1 g/dL or when active chorioretinitis threatens vision (see <a class="local">'Treatment of new-onset chorioretinitis'</a> below). Glucocorticoids are continued until elevated CSF protein or active chorioretinitis lesions are resolved. The benefit of adjunctive glucocorticoids in this setting is supported by observational data and expert opinion [<a href="#rid1">1,2,7</a>]; controlled trials are lacking.</p><p class="headingAnchor" id="H6013042"><span class="h4">Special considerations</span><span class="headingEndMark"> — </span>Special considerations are necessary for infants with any of the following [<a href="#rid1">1,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal insufficiency</strong> – <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">Sulfadiazine</a> is excreted in the kidney, and the dose may require adjustment for infants with renal insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucose-6-phosphate dehydrogenase (G6PD) deficiency</strong> – <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">Sulfadiazine</a> may cause hemolysis in infants with G6PD deficiency; <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> (20 to 30 mg/kg per day divided in four doses) may be substituted for sulfadiazine in infants with G6PD deficiency. The combination of <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> and clindamycin has been used to successfully treat toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome (AIDS) [<a href="#rid11">11-13</a>], and the authors of this topic have used it successfully in a child with severe G6PD deficiency. However, high-dose pyrimethamine has been reported to cause hemolytic anemia in some patients with G6PD deficiency, and such patients should be monitored closely. Combination antiparasitic therapy is recommended for treating <em>Toxoplasma</em> infection, so in children not able to take either pyrimethamine or sulfadiazine, clindamycin plus an alternative agent should be selected in consultation with an infectious disease expert.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergy to </strong><strong>sulfadiazine</strong> – For infants who develop an allergy to <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">sulfadiazine</a>, <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> may be substituted [<a href="#rid11">11</a>]. Desensitization has also been described [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medications</strong> – <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">Sulfadiazine</a> may prolong the half-life of <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> (via interference with hepatic microsomal enzymes) and decrease excretion rate of <a class="drug drug_pediatric" data-topicid="13170" href="/d/drug information/13170.html" rel="external">clonazepam</a>. Dosing adjustments may be necessary for these agents. Concomitant administration of <a class="drug drug_pediatric" data-topicid="13113" href="/d/drug information/13113.html" rel="external">carbamazepine</a> and <a class="drug drug_pediatric" data-topicid="13007" href="/d/drug information/13007.html" rel="external">zidovudine</a> may exacerbate bone marrow suppression and neutropenia.</p><p></p><p class="headingAnchor" id="H6012724"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The evidence for the efficacy of postnatal antiparasitic therapy for congenital toxoplasmosis comes from observational studies in infants, indirect evidence from clinical trials in adults with HIV, and in vitro studies [<a href="#rid10">10,11,15-18</a>]. There are no placebo-controlled randomized trials of antiparasitic therapy in infants. Cohort studies have demonstrated improved outcomes among treated infants compared with historical controls [<a href="#rid1">1,4,19,20</a>].</p><p>In the National Collaborative Chicago-Based Congenital Toxoplasmosis Study, 120 infants with congenital toxoplasmosis received 12 months of combination therapy (daily <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">sulfadiazine</a>, thrice-weekly folinic acid, plus two or six months of daily <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> followed by thrice-weekly pyrimethamine for the remainder of the year) [<a href="#rid1">1,19</a>]. Compared with historical controls (untreated or treated for one month), 12-month combination therapy was associated with improved neurologic, cognitive, ocular, and auditory outcomes over an average follow-up of 10.5 years [<a href="#rid19">19</a>]. Signs of active infection resolved within weeks in all treated infants who were evaluated [<a href="#rid10">10</a>]. Among infants with mild disease at birth (n = 24), all had normal cognitive, neurologic, and auditory outcomes; two infants (9 percent) developed new eye lesions. Among infants with moderate to severe disease at birth (n = 96), 72 percent had normal neurologic and cognitive outcomes and no patients had hearing loss. Approximately 85 percent had impaired vision, which was most often due to retinal disease present at birth; 36 percent developed new eye lesions during follow-up. There were no deaths in the mildly affected cohort and 11 deaths (11 percent) in the severely affected cohort. The average age at time of death was 4.9 years.</p><p>In another study, the New England Regional Toxoplasma Working Group described the outcomes of 49 infants identified through a serologic screening program [<a href="#rid4">4</a>]. The infants in this cohort had mild or subclinical infection without apparent disease at birth, though evaluation performed after being identified revealed elevated CSF protein, intracranial calcifications, or retinal lesions in 40 percent. Most infants were treated for one year (with the exception of one infant who died at two months of age and four others whose parents/caregivers discontinued treatment after six to eight months). Treatment regimens varied somewhat, but 40 of the 49 infants received the same regimen (<a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> daily for six months then every other day for six months, <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">sulfadiazine</a> twice daily for 12 months, and folinic acid adjusted for hematologic changes). After treatment, only one child had a neurologic deficit (hemiplegia that was attributed to a cerebral lesion present at birth). Among the 39 children who had ophthalmologic follow-up at one to six years of age, four had lesions that may have developed postnatally. These findings suggest that early and prolonged treatment of asymptomatic infants may reduce the risk of long-term sequelae.</p><p class="headingAnchor" id="H4829795"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>The main side effect of <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> is neutropenia, which often occurs in conjunction with a viral illness [<a href="#rid1">1,4,21</a>]. Neutropenia generally resolves when the folinic acid dose is increased. In some cases, modification of the pyrimethamine dose is required. Other adverse effects may include aplastic anemia, hepatotoxicity, and hypersensitivity.</p><p>Skin exanthems (hives, allergic dermatitis) are the most common allergic reactions to <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">sulfadiazine</a>. Severe sulfadiazine-associated neutropenia can occur rarely and should be considered if neutropenia persists despite increased doses of folinic acid and/or temporary discontinuation of <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> [<a href="#rid22">22</a>].</p><p>Administration of a second sulfonamide drug (eg, <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a>) during combination therapy with pyrimethamine-sulfadiazine should be avoided because it may result in sustained bone marrow suppression [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4829802"><span class="h3">Therapeutic monitoring</span><span class="headingEndMark"> — </span>Complete blood counts (CBCs) should be monitored during therapy to evaluate drug-induced neutropenia and hemolysis (for patients with G6PD deficiency). We suggest the following intervals for monitoring the CBC:</p><p class="bulletIndent1"><span class="glyph">●</span>Once per week after starting daily <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a>; the CBC can be spaced to every two weeks if counts remain stable</p><p class="bulletIndent1"><span class="glyph">●</span>Once per month when taking <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> every other day</p><p></p><p>The more frequent intervals should be used if there is an intercurrent illness or neutropenia. The folinic acid (<a class="drug drug_pediatric" data-topicid="12544" href="/d/drug information/12544.html" rel="external">leucovorin</a>) dose should be increased if the ANC falls below 1000 cells/microL. <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">Pyrimethamine</a> should be temporarily withheld if the ANC is below 500 cells/microL. Persistent neutropenia despite withholding pyrimethamine may be caused by <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">sulfadiazine</a>.</p><p>Liver and renal function tests (aspartate transaminase and alanine transaminase or gamma-glutamyl transferase, bilirubin, alkaline phosphatase, blood urea nitrogen, and creatinine) are monitored every three to six months and as needed for follow-up of abnormal results.</p><p class="headingAnchor" id="H4829816"><span class="h2">Disease monitoring</span><span class="headingEndMark"> — </span>Serologic follow-up is recommended for children with congenital toxoplasmosis until 18 months of age. Clinical follow-up is recommended throughout early childhood because of the risk of late sequelae. Routine ophthalmologic evaluations are especially important for infants and young children because they are unable to report changes in vision.</p><p>We suggest the following schedule for follow-up  (<a class="graphic graphic_table graphicRef128426" href="/d/graphic/128426.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serologies</strong> – Serum <em>Toxoplasma</em>-specific immunoglobulins G and M (IgG and IgM) determinations every three to six months until 18 months or completion of therapy, whichever is longer. This is especially important for unconfirmed but highly suspected cases. During treatment, <em>Toxoplasma</em>-specific IgM typically falls to undetectable levels, but it commonly increases once therapy is discontinued. Similarly, some children have <em>Toxoplasma</em>-specific IgG rebound several months after completion of therapy. The clinical significance of these rebound titers is uncertain, but obtaining serology at the end of treatment and at one, three, and six months off of treatment may be of diagnostic value for the unconfirmed, highly suspected cases [<a href="#rid1">1,23,24</a>]. (See  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Serology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – Periodic physical examination should include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurodevelopmental assessments (see  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Routine eye and vision assessments (see  <a class="medical medical_review" href="/d/html/6261.html" rel="external">"Vision screening and assessment in infants and children"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Hearing assessment (see  <a class="medical medical_review" href="/d/html/6297.html" rel="external">"Hearing loss in children: Screening and evaluation"</a>)</p><p></p><p class="bulletIndent1">These assessments focus on identifying late manifestations of congenital toxoplasmosis infection. (See  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Late manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye examination</strong> – Repeated eye examinations by an ophthalmologist experienced with identifying <em>Toxoplasma</em> chorioretinal lesions in infants and toddlers should be obtained every three months until the age of 18 months, then every 6 to 12 months. The frequency of examinations should be adjusted as needed if retinal disease is present. Ophthalmologic examination should be performed earlier than scheduled if any symptoms that may be related to ocular disease occur. Some specialists recommend ophthalmology follow-up every three to six months until the child is old enough to report vision changes reliably [<a href="#rid9">9</a>]. The risk of new or recurrent chorioretinal disease is known to persist into adulthood, so a schedule of every 6- to 12-month examinations may be useful through adolescence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic examination</strong> – Pediatric neurologic examination every three to six months until one to two years of age. The frequency and duration of pediatric neurology follow-up are determined by the presence of neurologic abnormalities. (See  <a class="medical medical_review" href="/d/html/15360.html" rel="external">"Detailed neurologic assessment of infants and children"</a>.)</p><p></p><p class="headingAnchor" id="H4829823"><span class="h2">Treatment of new-onset chorioretinitis</span><span class="headingEndMark"> — </span>New-onset active chorioretinitis occurring beyond the initial period of treatment should be treated with combination <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> (plus folinic acid) and <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">sulfadiazine</a> therapy. Many experts also treat vision-threatening lesions with glucocorticoids (ie, <a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> or <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a>) until acute inflammation resolves. However, it is unclear if adding a glucocorticoid to the treatment regimen improves efficacy [<a href="#rid25">25</a>]; some ophthalmologists use glucocorticoids only if there is clouding of the vitreous (vitreitis).</p><p>The doses for these agents are as follows [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">Pyrimethamine</a> 2 mg/kg (maximum 50 mg/dose) once daily for two days, then 1 mg/kg (maximum 25 mg/dose) once daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">Sulfadiazine</a> 75 mg/kg, then 12 hours later, 50 mg/kg twice per day</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Folinic acid (<a class="drug drug_pediatric" data-topicid="12544" href="/d/drug information/12544.html" rel="external">leucovorin</a>) 10 mg three times per week</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">Prednisolone</a> (or <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a>) 1 mg/kg per day divided in two doses; maximum 40 mg/day</p><p></p><p><a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">Pyrimethamine</a> and <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">sulfadiazine</a> are continued until approximately two weeks after acute inflammation has resolved [<a href="#rid3">3</a>]. Folinic acid is continued during pyrimethamine therapy and for one week after pyrimethamine is discontinued. <a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">Prednisolone</a> is continued until inflammation subsides and then is rapidly tapered (typical duration two to four weeks).</p><p>Acute inflammation often has a white, fluffy appearance but is not always easy to discern, especially when adjacent to an old pigmented scar. With appropriate treatment, acute lesions generally stabilize or resolve within four to eight weeks [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H6012039"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H3960044003"><span class="h2">Natural history of untreated disease</span><span class="headingEndMark"> — </span>The prognosis in untreated infants with overt congenital toxoplasmosis disease at birth is generally poor. This was demonstrated in a case series of 156 patients from the 1940s, of whom 152 had overt neurologic or generalized manifestations of disease [<a href="#rid27">27</a>]. Mortality was 12 percent. The majority of patients developed intellectual disability (93 percent), seizures (81 percent), spasticity/palsies (70 percent), and severely impaired vision (60 percent). Other sequelae included hydrocephalus or microcephaly (33 percent) and deafness (15 percent).</p><p>Children with subclinical infection also may develop cognitive, motor, auditory, and visual impairment, but it is unclear how commonly this occurs [<a href="#rid3">3,28-31</a>]. In some reports, new chorioretinitis lesions developed in up to 90 percent of children with untreated congenital <em>Toxoplasma</em> infection [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H1640688917"><span class="h2">Prognosis with treatment</span><span class="headingEndMark"> — </span>Early and prolonged treatment appears to reduce the risk of adverse neurologic and vision outcomes, as discussed above (see <a class="local">'Efficacy'</a> above). However, treated infants remain at risk for developing sequelae later in life [<a href="#rid3">3,22,32-36</a>]. Available antiparasitic drugs are active against the tachyzoite form of <em>T. gondii</em> but do not effectively eradicate the bradyzoite form from the eye and central nervous system (CNS). Thus, recurrence of eye and CNS disease may occur after cessation of treatment. Chorioretinitis can result in retinal damage and loss of vision, which should be monitored closely.(See <a class="local">'Disease monitoring'</a> above.)</p><p>Reported risk factors for poor neurologic outcome include [<a href="#rid1">1,19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe CNS disease apparent at birth</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged uncorrected hydrocephalus</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrospinal fluid (CSF) protein &gt;1 g/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral atrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Severe vision impairment</p><p class="bulletIndent1"><span class="glyph">●</span>Late diagnosis (ie, delayed initiation of treatment)</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate treatment course (several months or less)</p><p></p><p>Neurologic complications appear to be uncommon when combination therapy is initiated early (ie, in utero or within one to two months after birth) and continued for at least one year. However, late neurologic manifestations can rarely occur. In a prospective cohort study of 477 patients who were treated for congenital toxoplasmosis (pre- and/or postnatally) and followed for a median of 10.5 years, 2 percent developed late neurologic abnormalities, including hydrocephalus, seizures, encephalopathy, cortical atrophy, and aphasia [<a href="#rid36">36</a>].</p><p>New-onset or recurrent chorioretinitis develops in approximately one-third of treated patients and can occur years after stopping treatment [<a href="#rid19">19,36</a>]. In the prospective cohort study described above, 30 percent of treated infants developed chorioretinitis at a median age of 3.1 years (range 0 to 20.7 years), with peaks at 7 years and 11 to 13 years [<a href="#rid36">36</a>]. In this study, the majority of patients with chorioretinitis had normal vision (81 percent of those with unilateral lesions and 73 percent of those with bilateral lesions) and very few patients (&lt;2 percent) had deterioration in vision during follow-up.</p><p class="headingAnchor" id="H4829830"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Strategies for prevention include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of exposure</strong> – Avoiding exposure to sources of <em>Toxoplasma </em>is an important way to prevent infection. This is particularly important for seronegative women of childbearing age and immunocompromised patients. Specific avoidance measures are discussed separately. (See  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal screening</strong> – The diagnosis of toxoplasmosis during pregnancy and screening pregnant women for toxoplasmosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal treatment</strong> – Treatment of maternal toxoplasmosis during pregnancy to prevent fetal infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Dosing, administration, and side effects'</a> and  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Efficacy'</a>.)</p><p></p><p class="headingAnchor" id="H163746711"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113063.html" rel="external">"Society guideline links: Toxoplasmosis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111578.html" rel="external">"Society guideline links: TORCH infections"</a>.)</p><p class="headingAnchor" id="H4830879"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whom to treat</strong> – Decisions about initiating antiparasitic treatment for suspected congenital toxoplasmosis and follow-up testing should be made in consultation with a pediatric infectious disease specialist. Our approach is generally as follows (see <a class="local">'Whom to treat'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prenatal diagnosis</strong> – For infants diagnosed with congenital toxoplasmosis prenatally, we recommend antiparasitic treatment (whether or not the mother received treatment) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Prenatal diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptomatic infants</strong> – For infants with clinical findings compatible with congenital toxoplasmosis (eg, chorioretinitis, intracranial calcifications, and/or hydrocephalus) who have the diagnosis confirmed with serology or polymerase chain reaction (PCR), we recommend antiparasitic treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In addition, for symptomatic infants who are born to mothers with recent <em>Toxoplasma gondii</em> infection and those whose initial serology results are equivocal, we suggest antiparasitic treatment pending definitive testing (which can take months) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The approach to confirming the diagnosis is described in detail separately. In the absence of confirmative testing, alternative etiologies should be excluded. (See  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic infants</strong> – For infants with confirmed <em>T gondii</em> infection (with serology or PCR performed by a reference laboratory) who lack supportive clinical findings, we suggest antiparasitic treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In addition, it is reasonable to treat asymptomatic infants who have equivocal newborn serology, pending definitive testing (which may take months). Deferring treatment in these infants is a reasonable alternative; however, there is a risk of late sequelae in untreated congenital toxoplasmosis. (See  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Late manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment regimen</strong> – The choice of regimen depends on drug availability and the experience of the treating clinician or center. For most patients, we suggest a regimen consisting of <a class="drug drug_pediatric" data-topicid="12754" href="/d/drug information/12754.html" rel="external">pyrimethamine</a> <strong>plus</strong> <a class="drug drug_pediatric" data-topicid="12814" href="/d/drug information/12814.html" rel="external">sulfadiazine</a> (or sulfamerazine or sulfamethazine) <strong>plus</strong> folinic acid (<a class="drug drug_pediatric" data-topicid="12544" href="/d/drug information/12544.html" rel="external">leucovorin</a>) rather than other regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Sulfamerazine and sulfamethazine are not available in the United States. We suggest a 12-month course of therapy rather than shorter or longer courses (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Treatment regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – During therapy, complete blood counts (CBCs) should be monitored to evaluate drug-induced neutropenia and hemolysis; liver and renal function tests are monitored every three to six months. During and after treatment, all children should have clinical follow-up throughout early childhood to monitor for late sequelae  (<a class="graphic graphic_table graphicRef128426" href="/d/graphic/128426.html" rel="external">table 1</a>). Routine ophthalmologic evaluations are especially important for infants and young children because they are unable to report changes in vision.(See <a class="local">'Therapeutic monitoring'</a> above and <a class="local">'Disease monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – If untreated, most infants with symptomatic congenital toxoplasmosis develop serious long-term sequelae, including intellectual disability, seizures, motor deficits, impaired vision, hydrocephalus, and hearing loss. It is unclear how commonly these sequelae occur in infants with subclinical or asymptomatic infection. Early and prolonged treatment appears to reduce the risk of adverse neurologic and vision outcomes, but treated infants remain at risk for long-term sequelae, particularly new-onset or recurrent chorioretinitis. Long-term neurologic deficits generally correlate with the severity of disease at the time of diagnosis. (See <a class="local">'Natural history of untreated disease'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3114073240"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ruth Lynfield, MD, and Jennifer Lee, MD, MS, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">McAuley J, Boyer KM, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994; 18:38.</a></li><li><a class="nounderline abstract_t">Peyron F, L'ollivier C, Mandelbrot L, et al. Maternal and Congenital Toxoplasmosis: Diagnosis and Treatment Recommendations of a French Multidisciplinary Working Group. Pathogens 2019; 8.</a></li><li class="breakAll">Peyron F, Wallon M, Kieffer F, Garweg J. Toxoplasmosis. In: Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant, 8th ed, Wilson CB, Nizet V, Maldonado YA, Remington JS, Klein JO (Eds), Elsevier Saunders, Philadelphia 2016. p.949.</li><li><a class="nounderline abstract_t">Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994; 330:1858.</a></li><li class="breakAll">Department of Health and Human Services. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Available at: aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf (Accessed on May 02, 2019).</li><li><a class="nounderline abstract_t">Maldonado YA, Read JS, COMMITTEE ON INFECTIOUS DISEASES. Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics 2017; 139.</a></li><li class="breakAll">Toxoplasma gondii infections (toxoplasmosis). In: Red Book: 2021–2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.767.</li><li class="breakAll">Contopoulos-Ioannidis D, Montoya JG. Toxoplasma gondii (toxoplasmosis). In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG (Eds), Elsevier Saunders, Edinburgh 2012. p.1308.</li><li class="breakAll">McAuley JB, Boyer KM, Remington JS, McLeod RL. Toxoplasmosis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.2987.</li><li><a class="nounderline abstract_t">McLeod R, Mack D, Foss R, et al. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother 1992; 36:1040.</a></li><li><a class="nounderline abstract_t">Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992; 116:33.</a></li><li><a class="nounderline abstract_t">Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268.</a></li><li><a class="nounderline abstract_t">Dannemann BR, Israelski DM, Remington JS. Treatment of toxoplasmic encephalitis with intravenous clindamycin. Arch Intern Med 1988; 148:2477.</a></li><li><a class="nounderline abstract_t">Yamamoto K, Kutsuna S, Kato Y, et al. Sulfadiazine Hypersensitivity and Desensitization in Children With Congenital Toxoplasmosis: A Report on Two Cases. Pediatr Infect Dis J 2021; 40:324.</a></li><li><a class="nounderline abstract_t">Kravetz J. Congenital toxoplasmosis. BMJ Clin Evid 2008; 2008.</a></li><li><a class="nounderline abstract_t">Mack DG, McLeod R. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother 1984; 26:26.</a></li><li><a class="nounderline abstract_t">Weiss LM, Harris C, Berger M, et al. Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis 1988; 157:580.</a></li><li><a class="nounderline abstract_t">Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211.</a></li><li><a class="nounderline abstract_t">McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis 2006; 42:1383.</a></li><li><a class="nounderline abstract_t">Roizen N, Swisher CN, Stein MA, et al. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 1995; 95:11.</a></li><li><a class="nounderline abstract_t">Kieffer F, Thulliez P, Brézin A, et al. [Treatment of subclinical congenital toxoplasmosis by sulfadiazine and pyrimethamine continuously during 1 year: apropos of 46 cases]. Arch Pediatr 2002; 9:7.</a></li><li><a class="nounderline abstract_t">Guerina NG. Congenital infection with Toxoplasma gondii. Pediatr Ann 1994; 23:138.</a></li><li><a class="nounderline abstract_t">Wallon M, Cozon G, Ecochard R, et al. Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children. Eur J Pediatr 2001; 160:534.</a></li><li class="breakAll">Lynfield R, Ogunmodede F, Guerina NG. Toxoplasmosis. In: Oski's Pediatrics Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis CD, Jones MD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1351.</li><li><a class="nounderline abstract_t">Jasper S, Vedula SS, John SS, et al. Corticosteroids as adjuvant therapy for ocular toxoplasmosis. Cochrane Database Syst Rev 2017; 1:CD007417.</a></li><li><a class="nounderline abstract_t">Ozgonul C, Besirli CG. Recent Developments in the Diagnosis and Treatment of Ocular Toxoplasmosis. Ophthalmic Res 2017; 57:1.</a></li><li class="breakAll">Eichenwald HF. A study of congenital toxoplasmosis with particular emphasis on clinical manifestations, sequelae and therapy. In: Human Toxoplasmosis, Siim JC (Ed), Munksgaard, Copenhagen 1959.</li><li><a class="nounderline abstract_t">Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980; 66:767.</a></li><li><a class="nounderline abstract_t">Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1986; 1:254.</a></li><li><a class="nounderline abstract_t">Labadie MD, Hazemann JJ. [Contribution of health check-ups in children to the detection and epidemiologic study of congenital toxoplasmosis]. Ann Pediatr (Paris) 1984; 31:823.</a></li><li><a class="nounderline abstract_t">Stagno S, Reynolds DW, Amos CS, et al. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics 1977; 59:669.</a></li><li><a class="nounderline abstract_t">Mets MB, Holfels E, Boyer KM, et al. Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol 1996; 122:309.</a></li><li><a class="nounderline abstract_t">Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004; 113:1567.</a></li><li><a class="nounderline abstract_t">Berrébi A, Assouline C, Bessières MH, et al. Long-term outcome of children with congenital toxoplasmosis. Am J Obstet Gynecol 2010; 203:552.e1.</a></li><li><a class="nounderline abstract_t">Peyron F, Garweg JG, Wallon M, et al. Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance. Pediatr Infect Dis J 2011; 30:597.</a></li><li><a class="nounderline abstract_t">Wallon M, Garweg JG, Abrahamowicz M, et al. Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence. Pediatrics 2014; 133:e601.</a></li></ol></div><div id="topicVersionRevision">Topic 15835 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8054436" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30781652" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Maternal and Congenital Toxoplasmosis: Diagnosis and Treatment Recommendations of a French Multidisciplinary Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30781652" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Maternal and Congenital Toxoplasmosis: Diagnosis and Treatment Recommendations of a French Multidisciplinary Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7818637" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7818637" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28138010" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28138010" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28138010" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28138010" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1510391" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727093" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838183" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3190380" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of toxoplasmic encephalitis with intravenous clindamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33181786" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sulfadiazine Hypersensitivity and Desensitization in Children With Congenital Toxoplasmosis: A Report on Two Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19450322" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6383209" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3343528" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1520757" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Toxoplasmic encephalitis in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16619149" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7770286" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neurologic and developmental outcome in treated congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865553" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [Treatment of subclinical congenital toxoplasmosis by sulfadiazine and pyrimethamine continuously during 1 year: apropos of 46 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8015862" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Congenital infection with Toxoplasma gondii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11585075" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11585075" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28125765" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Corticosteroids as adjuvant therapy for ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27723657" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recent Developments in the Diagnosis and Treatment of Ocular Toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27723657" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Recent Developments in the Diagnosis and Treatment of Ocular Toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7432882" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2868264" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Results of 20-year follow-up of congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6517458" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : [Contribution of health check-ups in children to the detection and epidemiologic study of congenital toxoplasmosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/193086" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8794703" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Eye manifestations of congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173475" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term ocular prognosis in 327 children with congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633868" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term outcome of children with congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21278618" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24534412" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
